Exagen
Founded Year
2002Stage
IPO | IPOTotal Raised
$156.13MDate of IPO
9/19/2019Market Cap
0.05BStock Price
3.09About Exagen
Exagen is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, the company's Avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.
Missing: Exagen's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Exagen's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Exagen
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Exagen is included in 4 Expert Collections, including Medical Devices.
Medical Devices
8,633 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
2,623 items
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Biopharma Tech
1,568 items
Health IT
7,901 items
Exagen Patents
Exagen has filed 19 patents.
The 3 most popular patent topics include:
- Autoimmune diseases
- Coagulopathies
- Glucocorticoids

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
3/13/2014 | 12/20/2022 | Autoimmune diseases, Inflammations, Rare diseases, Rheumatology, Immune system | Grant |
Application Date | 3/13/2014 |
---|---|
Grant Date | 12/20/2022 |
Title | |
Related Topics | Autoimmune diseases, Inflammations, Rare diseases, Rheumatology, Immune system |
Status | Grant |
Latest Exagen News
May 30, 2023
05/30/2023 | 09:01am EDT Message : *Required fields SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 43rd Annual Growth Stock Conference, which takes place June 6-8, 2023, in Chicago at the Loews Chicago Hotel. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will present on Wednesday, June 7th, at 2:00 PM CT. Interested parties may access the webcast of the presentation using a link on Exagen’s website at https://investors.exagen.com/events . About Exagen Inc. Exagen is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions. Exagen is a patient focused, discovery driven organization built on the success of AVISE® testing and is investing in its product pipeline to support patients throughout their autoimmune diagnosis and treatment journeys. The goal at Exagen is to assist patients, physicians, and payors by enabling precision medicine. Exagen is located in San Diego County. For more information, please visit Exagen.com and follow @ExagenInc on Twitter. Forward Looking Statements Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect its business, financial condition and results of operations, including as a result of slowdown in its operations as well as those of its suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for its tests causing an increase in cost per test, its sales and commercialization activities and its ability to receive specimens and perform or deliver the results from its tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor Relations
Exagen Frequently Asked Questions (FAQ)
When was Exagen founded?
Exagen was founded in 2002.
Where is Exagen's headquarters?
Exagen's headquarters is located at 1261 Liberty Way, Vista.
What is Exagen's latest funding round?
Exagen's latest funding round is IPO.
How much did Exagen raise?
Exagen raised a total of $156.13M.
Who are the investors of Exagen?
Investors of Exagen include Tullis Health Investors, Cottonwood Technology Fund, Sun Mountain Capital, Innovatus Capital Partners, CRG and 7 more.
Who are Exagen's competitors?
Competitors of Exagen include CivaTech Oncology, Decipher Biosciences, Biodesix, Progentec Diagnostics, Integrated Diagnostics, Foundation Medicine, Daktari Diagnostics, Signature Diagnostics, On-Q-ity, SourceMDx and 12 more.
Compare Exagen to Competitors
CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.
NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
Predict to Prevent Prognomixs vision is the development of personalized medicine for the early detection of susceptibilities to diseases their complications and individual therapeutic responsiveness using genomic signatures Their initial focus is the development of presymptomatic diagnostic tools of diabetic complications based on genomic signatures aimed at individualized targeted prevention

Civatech Oncology is a medical device company focused on the development of polymer based devices that treat cancer using localized, low-dose-rate radiation. The company's fabrication methods allow for precise encapsulation of radioactive materials into polymer structures. These polymer-based brachytherapy devices offer physicians treatment options for tumors with low-dose-rate brachytherapy.
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.